Trial Profile
A randomized, double-blind, placebo-controlled Phase 3 study of SGN-35 (brentuximab vedotin) and best supportive care (BSC) versus placebo and BSC in the treatment of patients at high risk of residual Hodgkin lymphoma (HL) following autologous stem cell transplant (ASCT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Acronyms AETHERA
- Sponsors Seagen; Seattle Genetics; Takeda
- 13 Dec 2022 Results assessing the effect of the cumulative maintenance brentuximab vedotin dose on 2-year progression free survival in patients with high-risk relapsed/refractory classical Hodgkin lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 03 Dec 2021 Data was used from this trial and an observational study using a French National Hospital database to assess public health impact by combining clinical trial and real-world data RWD presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 04 Jul 2020 This trial is completed in Hungary (Global End Date: 07 May 2020), according to European Clinical Trials Database record.